Wayne State University

Warrior strong
Login
Search

School of Medicine

Cancer Biology

Research Projects

  • Current Research Projects

    Kenneth V. Honn, Principal Investigator CDMRP/DoD
    12-Lipoxygenase-Induced Prostate Cancer Radioresistance: A Pivotal Role for NF-kappaB Signaling
    P.I.: Kenneth V. Honn - Effort: 5% - Period 7/1/11 – 6/30/14
    Funding - (Direct) $366,400 / (Indirect) $190,528 / Total $556,928
    Fund for Cancer Research
    Role of GPR31, a high-affinity receptor of 12(S)-HETE, in prostate cancer progress
    P.I.: Honn, K.V. - Effort: 5% - Period 6/1/11 – 5/30/12- $75,000
    Strategic Research Initiative Grant (SRIG) – Karmanos Cancer Institute
    15-LOX1/2 as a novel Putative Tumor Suppressor and Potential Prognostic and Therapeutic Marker in Ovarian Cancer (CoI: K.V.Honn; PI: R. Ali-Fehmi) 2012-2013 - RFA#KCI-2012-1 - $50,000 Krishnarao Maddipati, Principal Investigator
    Krishnarao Maddipati, Principal Investigator

  • Pending Projects

    The A. Paul and Carol C. Schaap Fund at the Community Foundation for Southeast Michigan
    Matching Support-contingent on OVPR funding 2012-2013 - $50,000
    NIH/NCI
    Role of 12-HETER1, a high-affinity receptor of 12(S)-HETE, in prostate cancer progression
    R01 (PI: K.V. Honn) 12/1/12 – 11/30/17 1.2 Calendar months- $3.17 million
    NIH/NIBIB
    Multimodal Method for In-Situ Characterization of Cells Utilizing and Integrating NSOM, Raman-
    AFM and Cell Capturing System
    R01 (CoI: K.V. Honn, PI: G. Auner) 10/1/12 – 9/30/15 1.2 Calendar months - $3.75 million
    CDMRP/DoD
    Transformation of Novel and Emerging Technology for the Diagnosis and Treatment of
    Ovarian Cancer
    W81XWH-11-OCRP-TIA (CoI: K.V.Honn; PI: G. Auner) 2013-2018 - $2.5 million
    Ovarian Cancer Research Fund - Program Project Development Grant
    Use of Theranostic Biomarkers with Raman Spectroscopy for Surgical Guidance and
    Treatment
    (CoI: K.V. Honn; PI: A. Munkarah) 2013-2016 - $300,000/year
    Strategic Research Initiative Grant (SRIG) – Karmanos Cancer Institute
    (CoI: K.V.Honn; PI: R. Ali-Fehmi) 2012-2013 - RFA#KCI-2012-1 - $50,000
    15-LOX1/2 as a novel Putative Tumor Suppressor and Potential Prognostic and Therapeutic
    Marker in Ovarian Cancer
    CDMRP/DoD:
    PC120819: Lipoxygenase-Regulated Signature of Inflammation Pathways in Prostate Tumor Progression
    PI: Honn, Kenneth - 8/9/12 (Application) - $570,000 (direct & indirects)
    CDMRP/DoD:
    PC120842: A novel therapeutic utility of prostate tumor: antagonizing the 12(S)-HETE receptor by a natural eicosanoid 13(S)-HODE
    PI: Honn, Kenneth - 8/9/12 (Application) - $570,000 (direct & indirects)
    CDMRP/DoD:
    PC120864 : Role of 12-HETER1, a newly identified 12(S)-HETE receptor, in Prostate Cancer Radioresistance.
    PI: Honn, Kenneth - 8/9/12 (Application) - $564,858 (direct & indirects)
    CDMRP/DoD:
    PC120912: Use of a Novel Clinical Biomarker, 12HETER1, for Diagnosis, Targeted Therapy, and Surgical Guidance
    PI: Honn, Kenneth - 8/9/12 (Application) - $570,000 (direct & indirects)
    CDMRP/DoD:
    OC120354: Rheostat of pro and anti-inflammatory lipid receptor expression as novel biomarker for histological and Raman characterization of ovarian carcinoma
    PI: Honn, Kenneth - 7/18/12 (Application) - $250,000 (direct)

    CDMRP/DoD
    12-HETER1, a High Affinity receptor of 12(S)-Hydroxyeicosatetraenoic Acid (HETE): A Novel Prognostic Biomarker of Prostate Tumor.
    Co-PI. Honn, Kenneth - $375,000 (direct cost)

  • Past Projects

    Kenneth V. Honn, Principal Investigator

    1. Prostaglandins and Lysosomal Mediated Tumor Metastasis. WSU Research Development Fund. (P.I., K.V. Honn), 6/1/79 to 5/31/80, $6,760.
    2. New Approach for the Control of Tumor Metastasis. The Milheim Foundation for Cancer Research. (P.I., K.V. Honn), 7/1/80 to 6/30/81, $12,000.
    3. Evaluation of the Antimetastatic Effects of Bay g 6575. Miles Institute for Preclinical Pharmacology. (P.I. , K.V. Honn), 6/1/80 to 5/31/81, $3,000.
    4. Studies on Prostacyclin and Tumor Metastasis. NIH/NCI – R01-CA29405-1 (P.I., K.V. Honn), 10/1/80 to 9/30/83, $104,787.
    5. Studies on Thromboxane Synthetase Inhibitors and Cancer. Comprehensive Cancer Center of Metropolitan Detroit. (P.I., K.V. Honn), 10/1/80 to 9/31/81, $10,000.
    6. Studies on Thromboxane Synthetase Inhibitors as Antimetastatic Agents. American Cancer Society. (P.I., K.V. Honn), 1/1/81 to 12/31/82, $94,151.
    7. Thromboxanes: Role in Tumor Growth and Metastasis. NIH/NCI – R01-CA29997-1 (P.I., K.V. Honn), 4/1/81 to 3/31/84, $158,339.
    8. Continuing Studies on the Antitumor Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. (P.I., K.V. Honn), 2/1/81 to 1/31/ 82, $59,000.
    9. Studies on the Antimetastatic Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. (P.I., K.V. Honn), 2/1/81 to 1/31/82, $5, 060.
    10. Continuing Studies on the Antitumor Effects of BAY g 6575. Miles Institute for Preclinical Pharmacology. (P.I., K.V. Honn), 2/1/82 to 1/31/83, $ 57,000.
    11. Cancer Chemoprevention and Arachidonate Metabolism. NIH/NCI, R01 L.J. Marnett, K.V. Honn and B.F. Sloane, (P.I. L.J. Marnett), 8/1/82 to 7/31/85, $350,000.
    12. Evaluation of the Antitumor and/or Antimetastatic Activities of CGS-13080 and CGS-14854. Ciba-Geigy Corporation. (P.I., K.V. Honn), 10/1/82 to 9/30/83, $14,460.
    13. Evaluation of Antitumor and Antimetastatic Activities of Thromboxane Synthetase Inhibitors. Pfizer Corporation. (P.I., K.V. Honn), 10/1/82 to 9/30/83. $15,000.
    14. Development of Monoclonal Antibodies to Cathepsin B. HarperGrace Hospitals. K.V. Honn and B.F. Sloane, (P.I., K.V. Honn), 7/1/83 to 8/31/84, $127,000.
    15. Studies on Prostacyclin and Tumor Metastasis. NIH/NCI R01-CA29405-4 (P.I., K.V. Honn), 7/7/83 to 12/31/86, $189,183.
    16. Cathepsin B-like Cysteine Proteinases and Tumor Invasion. NIH/NCI R01-CA36481-1. B.F. Sloane and K.V. Honn, (P.I.,B.F. Sloane), 12/1/83 to 11/30/86, $341,000.
    17. Thromboxanes: Role in Tumor Growth and Metastasis. NIH/NCI R01 CA29997-4. (P.I.,K.V. Honn), 4/1/84 to 12/31/87, $341,113.
    18. Studies on Metastasis. Harper/Grace Hospitals. K.V. Honn, L.J. Marnett and B.F. Sloane, (P.I., K.V. Honn), 1/1/85 to 63086, $160,000.
    19. Studies on Metastasis. Thomae Pharaceutical. K.V. Honn and L.J. Marnett (P.I., K.V. Honn), 1/1/85 to 12/31/85, $60,000.
    20. Studies on Metastasis. Harper-Grace Hospitals. K.V. Honn, L.J. Marnett, B.F. Sloane, C.J. Johnson and J.M. Onoda (P.I., K.V. Honn), 12/1/85 to 8/31/87, $175,000.
    21. Development of Lipoxygenase Inhibitors. Harper/Grace Hospitals. K.V. Honn, L. J. Marnett, C. Johnson (P.I. K. V. Honn), 9/1/87 to 6/30/89, $250,000 (direct costs).
    22. Role of Platelets in Hematogenous Metastasis. American Cancer Society. (P.I., K.V. Honn), 1/1/86 to 12/31/87, $190,000.
    23. Role of Platelets in Hematogenous Metastasis. American Cancer Society. K.V. Honn (P.I. K.V. Honn) Interim Funding 1/1/88 to 6/30/89, $48,000.
    24. Studies on Radiporotection, Coagulation and Metastasis–Harper Grace Hospitals. J. M. Onoda and K.V. Honn (P.I. K. V. Honn), 10/1/88 to 9/30/89, $100,297 (direct costs).
    25. Studies on Metastasis. Thomae Pharmaceutical. K.V. Honn and L.J. Marnett, (P.I., K.V. Honn), 1/1/87 to 12/31/90, $60,000 (direct costs).
    26. Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI – R01-CA47115-1 (P.I. K.V. Honn), 5/1/88 to 4/31/92, $418,323 (direct costs).
    27. Studies on 12-Lipoxygenase–Ono Pharmaceuticals. K.V. Honn, C.R. Johnson, and L.J. Marnett (P.I. K.V. Honn). 1/1/89 to 12/31/92, $2,525,000 (direct costs).
    28. Studies on Radiporotection, Metastasis–Harper Grace Hospitals. J. M. Onoda and K.V. Honn (P.I. K. V. Honn), 1/1/90 to 12/31/93, $104,921 (direct costs).
    29. Supplemental Equipment Grant for Metastasis Program–Harper Grace Hospitals. J.M. Onoda and K.V. Honn (P.I. K.V. Honn), 5/1/91 to 9/30/94, $157,000 (direct costs).
    30. Cathepsin B-like Cysteine Proteinases and Tumor Invasion. NIH/NCI Bonus Grant R01-CA36481-4. B.F. Sloane and K.V. Honn, (P.I., B.F. Sloane), 7/1/87 to 6/30/93, $493,046 (direct costs).
    31. New Signal Transduction Pathways in Metastatic Melanoma Cells. NATO Linkage Grant (P.I. K.V. Honn) 1/1/93 to 12/31/95, $26,000 (direct costs).
    32. Signal Transduction in Tumor Metastasis. Fogarty International Research Collaboration Award. (P.I. K.V. Honn) 9/1/93 to 8/31/96, $60,000 (direct costs).
    33. Role of Endothelial Cell 12-Lipoxygenase and 12(S) HETE in Tumor Induced Angiogenesis. Cancer Research Foundation of America (P.I.., K.V. Honn) 1/1/97 to 12/31/97, $25,000 (direct costs).
    34. Role of Signaling in the Progression of Melanoma. NATO Linkage Grant (P.I., K.V. Honn) 1/1/95 to 12/31/97, $26,000 (direct costs).
    35. Studies on Metastasis, Harper Hospital Development Fund (P.I. K.V. Honn), 9/1/94 - 8/30/98, $248,000 (direct costs).
    36. Prognostic Markers for Prostate Cancer, Harper Hospital Development Fund, (P.I. K.V. Honn) 9/1/94 to 6/30/98, $99,000 (direct costs).
    37. Metastatic Studies: Potential Involvement of Integrin b in Tumor Progression and Metastasis). Harper Hospital Development, (P.I. K.V. Honn) 11/1/94 to 10/31/98, $100,000 (direct costs).
    38. Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI. R01CA47115-6, (P.I. K.V. Honn), 03/01/95 to 02/28/99, $1,178,331 (direct and indirect costs).
    39. Role of Endothelial Cell 12-Lipoxygenase and 12(S) HETE in Tumor Induced Angiogenesis. Cancer Research Foundation of America (P.I.., K.V. Honn) 04/15/97 to 04/15/99, $55,000 (direct costs).
    40. Studies on Metastasis. Harper Hospital Development Fund (P.I. K.V. Honn), 09/01/94 to 06/30/99, $248,000 (direct costs).
    41. Prognostic Markers for Prostate Cancer. Harper Hospital Development Fund (P.I. K.V. Honn), 09/01/94 to 06/30/99, $99,000 (direct costs).
    42. Bioactive Lipids: Role in Prostate Cancer Angiogenesis. DOD/Army (P.I., K.V. Honn) 9/30/98 to 3/30/01, $468,750 (direct and indirect costs).
    43. Arachidonate Acid 12-Lipoxygenase Inhibitors for Anti-Angiogenesis Therapy of Prostate Cancer. CAPCure (P.I. KV Honn), 01/01/99 to 12/31/01, $75,000.
    44. Role of Eicosanoids in Tumor Cell Metastasis. NIH/NCI. CA R0129997, (P.I. K.V. Honn), 02/01/96 to 01/31/00, $988,291.
    45. Development Grant - PCa Progression and Metastasis, NIH/NCI. CA1R21 69845-01 (P.I. K.V. Honn) 09/01/95 - 08/31/01, $1,028,820 (direct costs).
    46. Bioactive Lipids: Role in Prostate Cancer Angiogenesis, Part II. DoD Army-Phase II (competitive renewal) (P.I. K.V. Honn) 6/30/01 - 6/29/03, $552,276 (direct + indirect costs).
    47. Ectopic Expression of Platelet Integrin aIIbb3 and the Progression of Human Melanoma. NATO Linkage Grant (P.I. K.V. Honn), 04/15/99 to 03/31/2001, $11,500 (direct costs).
    48. Thromboxane Synthase as a Target for Anti-Angiogenesis Therapy of Prostate Cancer. Cancer Research Foundation of America. (P.I. K.V. Honn) 4/15/01-4/14/03, $60,000 (direct costs only).
    49. Randomized Clinical Trial of Zileuton in Persons with Bronchial Dysplasia, NIH/NCI – Contract NO1-CN-05022 (O. Kucuk, H. Pass, T. Budd, K.V.Honn (P.I. O. Kucuk) ), 9/01/01-9/01/05, $1,402,882 (total direct).
    50. Thromboxane Synthase and Prostate Cancer Progression, DoD/Army, (P.I. K.V. Honn), 12/1/01 - 07/15/05, $558,750.
    51. Formulation and Evaluation of a Prostate Cancer Drug, Phase 1, NIH STTR Phase 1 – 1 R41 CA97863-01 (P.I. K.V. Honn), 10/01/02-2/28/06, $148,000.
    52. Formulation and Evaluation of a Prostate Cancer Drug, Phase 1, NIH STTR Phase 1 – 1 R41 CA97863-01 (P.I. K.V. Honn), 10/01/02-2/28/06, $148,000.
    53. Eicosanoid Regulation of Prostate Cancer Progression: Disruption of Hemidesmosomes and Collaboration in Tumor Invasive Growth, Department of Defense – DAMD17-03-1-0102 (P.I. K.V. Honn), 4/01/03-3/31/07, $ 558,472.
    54. Naturally Occurring Truncated b3 Integrins (aIIbb3 and avb3) In Prostate Cancer Metastasis. -Department of Defense - W81XWH-04-1-0144 (P.I. Rongxian Jin), Postdoctoral Traineeship Award, 01/01/04 - 1/31/07, $98,000.
    55. Faculty Graduate Research Assistantship. Wayne State University (Internal) (P.I. K.V. Honn), Stipend for graduate student, 8/15/05 - 08/14/06, $20,500.
    56. Tumor Cell Adhesive Glycoproteins and Metastasis. NIH/NCI – 2 R01 CA47115-09A2 (P.I. K.V. Honn) (competitive renewal), 8/01/01-7/31/06, $1,487,060.
    57. 12-Lipoxygenase as a Target for Radiosensitization, NIH/STTR – 1 R41 CA103564-01A2 (P.I. K.V. Honn), 04/01/05 – 03/31/07, $99,744 (direct and indirect costs).
    58. Role of Eicosanoids in Tumor Cell Metastasis. NIH – 5 R01 CA029997-18 (P.I. K.V. Honn). 4/01/04-3/31/10, $1,359,00 (direct and indirect costs).
    59. Characterization of a Novel 12(S)-HETE Receptor and Role in Prostate Cancer Progression. DOD – W81XWH-06-1-0226 (P.I. K.V. Honn), 12/30/05 - 1/30/10, $565,398 (direct and indirect costs).
    60. 12-Lipoxygenase and Prostate Cancer Angiogenesis. Fund for Cancer Research (P.I. K.V. Honn), 08/15/07 – 08/14/10, $75,000 (no indirects).
    61. Role of Thromboxane in Prostate Cancer Progression. NIH/NCI – 1 R01 CA114051-01A1 (P.I. K.V. Honn), 08/15/06 – 07/31/11, $1,618.313 (direct and indirect costs).
    62. 12-Lipoxygenase-Induced Prostate Cancer Angiogenesis and Resistance to Antiangiogenic Therapy. DOD (P.I. K.V. Honn), 09/01/08 – 09/30/11, $563,494 (direct and indirect costs).
    63. Role of GPR31, a high-affinity receptor of 12(S)-HETE, in prostate cancer progress. Fund for Cancer Research, (P.I.: Honn, K.V). - Period 6/1/11 – 5/30/12- $75,000 (no indirects)

    Krishnarao Maddipati, Principal Investigator

    Purification and Crystallization of Human 12-LOX Enzymes. NIH/STTR (P.I. K. Maddipati), 9/1/04 - 9/30/05, $99,864.

    Anticancer Prodrug Developement Program. Michigan Technology Tri-Corridor (P.I. K.Maddipati), 9/1/05- 8/31/08, $569,977.